To improve early and minimally invasive diagnosis and bring it closer to the patient.
To become a leading company in the development of products and solutions for early, sensitive and non-invasive diagnostics in areas such as cancer, infectious diseases and immune diseases.
Leading-edge research products to increase the analysis potential.
Extensive Research, Development and Innovation (R&D&I) Programme.
Seeking efficency and offering alternative to traditional solutions.
Succesful technology licensing and meaningful worldwide collaborations.
We work to achieve customer satisfaction through quality and differentiation of our products. We are constantly learning and developing as a company and, in the same way, we expect our products and our way of working to be constantly improving for the benefit of all our collaborators.
We find the most innovative technology and use them to build adaptive clinical products to diagnose and treat diseases, and we work to achieve our goals under a strict system of values:
We seek always to be at the leading-edge of technology in research areas of development, and in order to achieve that goal, we work under an aggressive R&D program headed by a brilliant scientific team.
Immunostep has a strong support for a renewal of investment in science and technology in order to support the development of the scientific community and its research efforts on a global scale.
Intensifying our commitment of providing high quality products, Immunostep works under UNE-EN ISO 13485: 2018 certified quality management system, which meets international standards for medical device and reagent manufacturing.
The social wellbeing of our employees, suppliers and local communities is our concern as a responsible overall activity. We evaluate the environmental and social impacts of all of the projects we invest in and work with our clients to achieve good international standards.
In 2017 Immunostep I+D team recognized the great potential of exosomes and since then we have been working on the development of a method for detecting, isolate and quantifying extracellular vesicles which are present in fluid samples.
As a response to SARs-CoV-2 global emergency we have developed a product line in order to improve serological testing performance and help building clinical investigation around Covid-19 disease.